Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
1 - 10 of 74
- Druglike FAPIs with maximal target residence time: chemical discovery and biological characterization.From1 Jan 2024 → TodayFunding: IOF - technology concept exploration
- Potent intra-tumoral autophagy blocking with kinase PROTACs and inhibitors.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Cell-type specific delivery of autophagy inducers as a strategy to address localized autophagy impairment in diseaseFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Directed optimization of highly selective DPP9 inhibitors for chemical biology and translational research.From1 Nov 2023 → TodayFunding: FWO fellowships
- Characterization and validation of novel autophagy inducers identified via high-throughput screening: a therapeutic option for the treatment of advanced atherosclerosis.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- AUTAC- and PROTAC-mediated degradation of DPP9 to induce pyroptosis: a novel treatment strategy in acute myeloid leukemia.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure (PaCaNano).From1 Sep 2023 → TodayFunding: FWO research project (including WEAVE projects)
- OncoProToolsFrom1 Jun 2023 → TodayFunding: BOF - projects
- DPP9 degradation-induced pyroptosis for treatment of acute myeloid leukemia (DPP9-TACDrug).From1 Apr 2023 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Diagnostic and theranostic targeting of fibroblast activation protein (FAP) with goed nanoparticles decorated with FAPIs and FAPI fragments.From1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
111 - 120 of 129
- A prolyl oligopeptidase inhibitor, KYP-2047, reduces $\alpha$-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease(2012)
Authors: T.T. Myöhänen, M.J. Hannula, Roos Van Elzen, M. Gerard, Pieter Van Der Veken, J.A. García-Horsman, V. Baekelandt, P.T. Männistö
Pages: 1097 - 1113 - Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs)(2011)
Authors: Muthusamy Venkatraj, Jan Heeres, Bertrand Dirié, Jurgen Joossens, Sebastiaan van Goethem, Pieter Van Der Veken, Johan Michiels, Koen Augustyns
Pages: 5924 - 5934 - Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9)(2011)
Authors: Sebastiaan van Goethem, Veerle Matheeussen, Jurgen Joossens, Xin Chen, Ingrid De Meester, Achiel Haemers, Koen Augustyns, Pieter Van Der Veken
Pages: 5737 - 5746 - Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries(2011)
Authors: Veerle Matheeussen, Lesley Baerts, Guido De Meyer, Gilles De Keulenaer, Pieter Van Der Veken, Koen Augustyns, Véronique Dubois, Simon Scharpe, Ingrid De Meester
Pages: 189 - 198 - $\_alpha$-ketoheterocycles as inhibitors of **Leishmania mexicana** cysteine protease CPB(2010)
Authors: Koen Steert, Maya Berg, Jeremy C. Mottram, Gareth D. Westrop, Graham H. Coombs, Paul Cos, Jurgen Joossens, Pieter Van Der Veken, Achiel Haemers, Koen Augustyns
Pages: 1734 - 1748 - Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy?(2010)
Authors: Maya Berg, Pieter Van Der Veken, A. Goeminne, Achiel Haemers, Koen Augustyns
Pages: 2456 - 2481 - Evaluation of nucleoside hydrolase inhibitors for the treatment of African trypanosomiasis(2010)
Authors: Maya Berg, Pieter Van Der Veken, Jurgen Joossens, Mohammed I. -al Salabi, Valeria Castagna, Francesca Giannese, Paul Cos, Wim Versées, Jan Steyaert, Philippe Grellier, et al.
Pages: 1900 - 1908 - Multi-slice computed tomography with N1177 identifies ruptured atherosclerotic plaques in rabbits(2010)
Authors: Jozef Leo van Herck, Guido De Meyer, Wim Martinet, Rodrigo Salgado, Bharati Shivalkar, Roel De Mondt, Helene Van de Ven, Annick Ludwig, Pieter Van Der Veken, Hidde Bult, et al.
Pages: 51 - 59 - Design and evaluation of **Trypanosoma brucei** metacaspase inhibitors(2010)
Authors: Maya Berg, Pieter Van Der Veken, Jurgen Joossens, Venkatraj Muthusamy, Matthias Breugelmans, Catherine X. Moss, Jana Rudolf, Paul Cos, Graham H. Coombs, Achiel Haemers, et al.
Pages: 2001 - 2006 - Synthesis of bicyclic **N**-arylmethyl-substituted iminoribitol derivatives as selective nucleoside hydrolase inhibitors(2009)
Authors: Maya Berg, Gunther Bal, Annelies Goeminne, Pieter Van Der Veken, Wim Versées, Jan Steyaert, Achiel Haemers, Koen Augustyns
Pages: 249 - 260
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)